J. Wollenhaupt

发表

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

Désirée van der Heijde, Didier Laurent, Dominique Baeten, 2013, The Lancet.

Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers.

J. Braun, J. Listing, A. Zink, 2000, The Journal of rheumatology.

[S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs].

C. Baerwald, H. Sitter, U. Müller-Ladner, 2018, Zeitschrift fur Rheumatologie.

Patient and Physician Expectations of Add‐On Treatment With Golimumab for Rheumatoid Arthritis: Relationships Between Expectations and Clinical and Quality of Life Outcomes

C. Zerbini, P. Durez, B. Combe, 2014, Arthritis care & research.

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Stanley B. Cohen, X. Mariette, E. Lee, 2017, Annals of the rheumatic diseases.

Prioritizing the patient: optimizing therapy in rheumatoid arthritis. Results of a patient questionnaire in northern Germany

J. Wollenhaupt, A. Groenewegen, I. Ehlebracht-Koenig, 2013, Open access rheumatology : research and reviews.

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

R. Collins, C. Gordon, D. Isenberg, 2016, Arthritis & rheumatology.

Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis

L. Takiya, J. Tesser, J. Wollenhaupt, 2020, Clinical Rheumatology.

Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.

G. Schett, K. Papp, R. Stevens, 2012, Arthritis and rheumatism.

Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.

D. Gladman, P. Mease, P. Nash, 2004, Arthritis and rheumatism.

Evaluation of amplicor chlamydia PCR and LCX chlamydia LCR to detect Chlamydia trachomatis in synovial fluid.

H. Zeidler, L. Köhler, J. Wollenhaupt, 2002, Clinical and experimental rheumatology.

Chlamydia and Borrelia DNA in synovial fluid of patients with early undifferentiated oligoarthritis: results of a prospective study.

H. Zeidler, J. Wollenhaupt, J. Kuipers, 2001, Arthritis and rheumatism.

Glucocorticoid receptors in rheumatoid arthritis.

R. Schlaghecke, C. Specker, J. Wollenhaupt, 1992, Arthritis and rheumatism.

Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.

Yeong-Wook Song, Sung-Hwan Park, L. Myasoutova, 2016, Rheumatology.

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

Stanley B. Cohen, X. Mariette, E. Lee, 2020, RMD open.

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis

H. Genant, W. Grassi, C. Peterfy, 2014, Annals of the rheumatic diseases.

Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160

R. Landewé, E. Matteson, J. Smolen, 2012, Annals of the rheumatic diseases.

Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.

M. Dougados, N. Goel, P. Emery, 2012, Rheumatology.

German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs

C. Baerwald, Matthias Schneider, U. Müller-Ladner, 2013, Rheumatology International.

Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol

D. M. van der Heijde, D. Heijde, A. Deodhar, 2013, Annals of the rheumatic diseases.

Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies

L. Takiya, R. V. van Vollenhoven, R. Fleischmann, 2017, RMD Open.

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies

E. Lee, C. Nduaka, J. Curtis, 2014, The Journal of Rheumatology.

Detection of Chlamydia trachomatis in peripheral blood leukocytes of reactive arthritis patients by polymerase chain reaction.

H. Zeidler, L. Köhler, J. Wollenhaupt, 1998, Arthritis and rheumatism.

Oral abstracts 1: SpondyloarthropathiesO1. Detecting axial spondyloarthritis amongst primary care back pain referrals

C. Cooper, D. Gladman, W. Tillett, 2012 .

BSR AND BHPR ORAL PRESENTATION OF ABSTRACTS ORAL ABSTRACTS 1: SPONDYLOARTHROPATHIES

D. Gladman, R. Landewé, P. Emery, 2012 .

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure

D. Gladman, D. M. van der Heijde, R. Landewé, 2015, RMD Open.

Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials

D. Gladman, E. Lespessailles, J. Gómez-Reino, 2020, ACR open rheumatology.

Lyme disease in a 74-year-old forest owner with symptoms of dermatomyositis.

G. Stanek, H. Zeidler, M. Follmann, 1995, Arthritis and rheumatism.

Sensitivities of PCR, MicroTrak, ChlamydiaEIA, IDEIA, and PACE 2 for purified Chlamydia trachomatis elementary bodies in urine, peripheral blood, peripheral blood leukocytes, and synovial fluid

H. Zeidler, J. Wollenhaupt, K. Scharmann, 1995, Journal of clinical microbiology.

Humoral immune response to the chlamydial heat shock proteins hsp60 and hsp70 in Chlamydia-associated chronic salpingitis with tubal occlusion.

J. Wollenhaupt, S. Dieterle, 1996, Human reproduction.

SAT0234 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years

J. Wollenhaupt, J. Silverfield, S. Strengholt, 2015, Saturday, 16 JUNE 2018.

The efficacy and safety of abatacept in methotrexate-naive patients with early erosive rheumatoid arthritis and poor prognostic factors

H. Genant, W. Grassi, C. Peterfy, 2008 .

Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab

R. Moots, C. Zerbini, K. Pavelka, 2016, Rheumatology.

Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study

C. Zerbini, P. Durez, B. Combe, 2013, Annals of the rheumatic diseases.

The new 2012 German recommendations for treating rheumatoid arthritis

U. Müller-Ladner, K. Krüger, J. Wollenhaupt, 2013, Zeitschrift für Rheumatologie.

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Stanley B. Cohen, J. Curtis, J. Wollenhaupt, 2019, Arthritis Research & Therapy.

PMS61 Rapid Reductions in Fatigue and Sleep Problems and Correlation with Improvements in Patient-Reported Outcomes in Patients with Active RA Treated with Certolizumab Pegol in the realistic 12-Week Phase IIIB Randomised Controlled Study

M. Dougados, M. Weinblatt, C. Bingham, 2011 .

FRI0179 Comparison of tocilizumab as monotherapy or in combination with non-biological disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) and an inadequate response to anti-TNF agents

V. Bykerk, J. Sibilia, A. Östör, 2013 .

FRI0242 Time to achieve remission and sustained remission for mtx-naïve patients with early ra treated with abatacept plus mtx versus mtx alone in the agree trial

W. Grassi, C. Poncet, J. Smolen, 2013 .

Intracellular persistence of chlamydial major outer-membrane protein, lipopolysaccharide and ribosomal RNA after non-productive infection of human monocytes with Chlamydia trachomatis serovar K.

E. Manor, H. Zeidler, J. Wollenhaupt, 1993, Journal of medical microbiology.

Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clinical trial.

G. Burmester, C. Antoni, J. Wollenhaupt, 2008, Clinical and experimental rheumatology.

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis

A. Gottlieb, D. Gladman, D. M. van der Heijde, 2018, RMD Open.

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

D. M. van der Heijde, D. Heijde, A. Deodhar, 2013, Annals of the rheumatic diseases.

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

M Cutolo, S Ramiro, M. Dougados, 2015, Annals of the rheumatic diseases.

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

D. Gladman, E. Lespessailles, J. Gómez-Reino, 2014, Annals of the rheumatic diseases.

Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.

D. Gladman, P. Tak, M. Genovese, 2011, Arthritis and rheumatism.

Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study

R. Landewé, E. Matteson, J. Smolen, 2015, Arthritis Research & Therapy.

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

D. M. van der Heijde, P. Tak, P. Emery, 2013, Annals of the rheumatic diseases.

[Psoriatic arthritis : Overview of drug therapy options and administration characteristics].

K. Krüger, D. Thaçi, J. Wollenhaupt, 2017, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[Psoriatic arthritis : Overview of drug therapy options and administration characteristics].

K. Krüger, D. Thaçi, J. Wollenhaupt, 2016, Zeitschrift fur Rheumatologie.

Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis

D. Gladman, E. Lespessailles, J. Gómez-Reino, 2015, The Journal of Rheumatology.

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies

D. Gladman, E. Lespessailles, J. Gómez-Reino, 2018, RMD Open.

LB0001 Long-Term (52-Week) Results of a Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis

P. Mease, A. Kavanaugh, R. Stevens, 2013 .

FRI0470 Long-Term (156-Week) Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials

G. Schett, A. Kavanaugh, S. Hall, 2016 .

OP0078 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-WEEK) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials

G. Schett, R. Stevens, J. Gómez-Reino, 2014 .

EFFECT OF CERTOLIZUMAB PEGOL ON SIGNS AND SYMPTOMS IN PATIENTS WITH PSORIATIC ARTHRITIS WITH OR WITHOUT PRIOR ANTI-TNF EXPOSURE : 24-WEEK RESULTS OF A PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY

P. Mease, R. Fleischmann, D. Kielar, 2012 .

Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes

H. Genant, W. Grassi, C. Peterfy, 2011, Annals of the rheumatic diseases.

Classification of Sneddon's syndrome.

K. Weissenborn, S. Schellong, C. Ehrenheim, 1997, VASA. Zeitschrift fur Gefasskrankheiten.

Complicated Cogan's syndrome with aortic insufficiency and coronary stenosis.

H. Zeidler, R. Laszig, T. Witte, 1994, The Journal of rheumatology.

5 Bacterial antigens in reactive arthritis and spondarthritis. Rational use of laboratory testing in diagnosis and follow-up

J. Wollenhaupt, J. Kuipers, S. Schnarr, 1998 .

lntracellular persistence of chlamydial major outer-membrane protein , lipopolysaccharide and ribosomal RNA after non-productive infection of human monocytes with Chlamydia trachomatis serovar

J. Wollenhaupt, M. Hammer, E. Schmitz, 2008 .

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

Tamas Koncz, David Gruben, Ricardo Blanco, 2013, The Lancet.

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

H. Genant, W. Grassi, C. Peterfy, 2009, Annals of the rheumatic diseases.

Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1

V. Mazurov, J. Lenaerts, L. Myasoutova, 2013, Annals of the rheumatic diseases.

Reactive and undifferentiated arthritis in North Africa: use of PCR for detection of Chlamydia trachomatis

M. Dougados, T. Vischer, H. Zeidler, 2008, Clinical Rheumatology.

Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity

M. Dougados, M. Weinblatt, C. Bingham, 2015, Arthritis Research & Therapy.

Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review.

E. Lee, Yoshiya Tanaka, J. Curtis, 2021, Clinical and experimental rheumatology.

Comparing 10-day and 4-month doxycycline courses for treatment of Chlamydia trachomatis-reactive arthritis: a prospective, double-blind trial

H. Zeidler, J. Wollenhaupt, J. Kuipers, 2006, Annals of the rheumatic diseases.

Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib

P. Nash, V. Azevedo, L. Bessette, 2021, Rheumatology and Therapy.

[Therapy with not yet approved drugs or for not yet approved indications].

J. Wollenhaupt, 2001, Zeitschrift fur Rheumatologie.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

Mahboob Rahman, R. Landewé, E. Matteson, 2009, The Lancet.

Gender-specific association between childhood trauma and rheumatoid arthritis: a case-control study.

S. Barnow, C. Spitzer, H. Grabe, 2013, Journal of psychosomatic research.

Gender-speci fi c association between childhood trauma and rheumatoid arthritis : A case – control study

S. Barnow, C. Spitzer, H. Grabe, 2013 .

[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm].

Andreas Krause, C. Baerwald, U. Müller-Ladner, 2012, Zeitschrift fur Rheumatologie.

THU0274 Double-blind, placebo-controlled, 28-week trial of efficacy and safety of infliximab plus naproxen vs naproxen alone in patients with early, active axial spondyloarthritis treated with a submaximal dose of NSAIDS: Preliminary results of INFAST part I

V. Mazurov, L. Myasoutova, J. Sieper, 2013 .

Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2

V. Mazurov, J. Lenaerts, L. Myasoutova, 2013, Annals of the rheumatic diseases.

Evaluation of ELISA to detect Chlamydia trachomatis antigen in urine samples from arthritis patients.

H. Zeidler, L. Köhler, M. Frosch, 1997, Clinical and experimental rheumatology.

Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria

M. Aringer, G. Burmester, T. Mosch, 2011, Annals of the rheumatic diseases.

OP0169 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase 3, Randomized, Controlled Trials

D. Gladman, E. Lespessailles, P. Mease, 2015 .

Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies

D. M. van der Heijde, R. Landewé, J. Wollenhaupt, 2020, Rheumatology.

210. Effect of Certolizumab Pegol Over 48 Weeks on Signs and Symptoms in Patients with Psoriatic Arthritis with and Without Prior Tumor Necrosis Factor Inhibitor Exposure

D. Gladman, D. Heijde, A. Deodhar, 2014 .

AB0364 A Novel Approach for Rheumatoid Arthritis: Results of The Ongoing Clinical Trials with The Fully Human Immunocytokine Dekavil (F8-IL10)

P. Sarzi-Puttini, R. Caporali, L. Bazzichi, 2016 .

Intra-articular co-infection by Borrelia burgdorferi and Chlamydia trachomatis

H. Zeidler, J. Wollenhaupt, J. Kuipers, 2001, Annals of the rheumatic diseases.

217. Long-Term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)

D. Gladman, E. Lespessailles, J. Gómez-Reino, 2015 .

Undifferentiated arthritis and reactive arthritis.

H. Zeidler, J. Wollenhaupt, 1998, Current opinion in rheumatology.

THU0179 Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-label, Long-term Extension up to 6 Years

A. Anisfeld, H. Nakamura, J. Wollenhaupt, 2015 .

Manifestations of Chlamydia induced arthritis in patients with silent versus symptomatic urogenital chlamydial infection.

H. Zeidler, J. Wollenhaupt, T. Krech, 1995, Clinical and experimental rheumatology.

Muscle disorders111. The impact of fatigue in patients with idiopathic inflammatory myopathy: a mixed method study

R. Moots, P. Salkovskis, Yulia Goryachev, 2012 .

OP0077 Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Psoriatic Arthritis with and without Prior Anti-Tumor Necrosis Factor Exposure: 96-Week Outcomes from the Rapid-Psa Trial

D. Gladman, A. Deodhar, R. Fleischmann, 2014 .

Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure.

D. Gladman, A. Deodhar, P. Mease, 2014 .

arthritis and poor prognostic factors rheumatoid methotrexate-naive patients with early Clinical efficacy and safety of abatacept in

W. Grassi, B. Haraoui, P. Durez, 2009 .

Oral Abstracts 7: RA ClinicalO37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach

H. L. Wright, R. Moots, T. Spector, 2013 .

International Conference on NeuroEndocrine Immunology in Rheumatic Diseases Steroids in NeuroEndrocrine Immunology and Therapy of Rheumatic Diseases

J. Aldag, J. Gómez-Reino, P. Mease, 2013 .

Befragung zu den Arbeits-, Weiterbildungs- und Forschungsbedingungen von Assistenzärztinnen und -ärzten in der internistisch-rheumatologischen Weiterbildung – BEWUSST

Andreas Krause, C. Specker, M. Krusche, 2023, Zeitschrift fur Rheumatologie.

Humoral immune response to the chlamydial heat shock proteins hsp60 and hsp70 in Chlamydia-associated chronic salpingitis with tubal occlusion.

J. Wollenhaupt, S. Dieterle, 1996, Human reproduction.